Home LiteratureArticle Details
PMID: 15596806 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle.

Journal of virology ·Vol. 79 ·No. 1 ·2005-01-00 ·Pages 106-15

Abrahamyan LG, Mkrtchyan SR, Binley J, Lu M, Melikyan GB, Cohen FS

Abstract

Effects of the cytoplasmic tail (CT) of human immunodeficiency virus type 1 Env on the process of membrane fusion were investigated. Full-length Env (wild type [WT]) and Env with its CT truncated (DeltaCT) were expressed on cell surfaces, these cells were fused to target cells, and the inhibition of fusion by peptides that prevent Env from folding into a six-helix bundle conformation was measured. For both X4-tropic and R5-tropic Env proteins, DeltaCT induced faster fusion kinetics than did the WT, and peptides were less effective at inhibiting DeltaCT-induced fusion. We tested the hypothesis that the inhibitory peptides were less effective at inhibiting DeltaCT-induced fusion because DeltaCT folds more quickly into a six-helix bundle. Early and late intermediates of WT- and DeltaCT-induced fusion were captured, and the ability of peptides to block fusion when added at the intermediate stages was quantified. When added at the early intermediate, the peptides were still less effective at inhibiting DeltaCT-induced fusion but they were equally effective at preventing WT- and DeltaCT-induced fusion when added at the late intermediate. We conclude that for both X4-tropic and R5-tropic Env proteins, the CT facilitates conformational changes that allow the trimeric coiled coil of prebundles to become optimally exposed. But once Env does favorably expose its coiled coil to inhibitory peptides, the CT hinders subsequent folding into a six-helix bundle. Because of this facilitation of maximal exposure and hindrance of bundle formation, the coiled coil is optimally exposed for a longer time for WT than for DeltaCT. This accounts for the greater peptide inhibition of WT-induced fusion.

MeSH Terms
CD4 Antigens/metabolism Cell Fusion Cell Line Flow Cytometry Gene Deletion HIV Envelope Protein gp41/chemistry,genetics,metabolism HIV Fusion Inhibitors/pharmacology HIV-1/pathogenicity HeLa Cells Humans Membrane Fusion/drug effects Protein Conformation Protein Folding Receptors, CCR5/metabolism Receptors, CXCR4/metabolism
Chemicals
CD4 Antigens HIV Envelope Protein gp41 HIV Fusion Inhibitors Receptors, CCR5 Receptors, CXCR4
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Abrahamyan Levon G
Department of Molecular Biophysics and Physiology, Rush University Medical Center, Chicago, Illinois 60612, USA.
Mkrtchyan Samvel R
Binley James
Lu Min
Melikyan Grigory B
Cohen Fredric S
References (58)
58 references, click to expand
  1. Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates.
    J Virol. 2002 Jul;76(13):6780-90 PMID: 12050391
  2. Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein.
    J Virol. 2002 Mar;76(6):2683-91 PMID: 11861835
  3. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
    Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16249-54 PMID: 12444251
  4. Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors.
    J Virol. 2003 Jan;77(2):1610-3 PMID: 12502877
  5. HIV-1 envelope proteins complete their folding into six-helix bundles immediately after fusion pore formation.
    Mol Biol Cell. 2003 Mar;14(3):926-38 PMID: 12631714
  6. Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions.
    J Virol. 2003 May;77(10):5678-84 PMID: 12719560
  7. Human immunodeficiency virus type 1 Env with an intersubunit disulfide bond engages coreceptors but requires bond reduction after engagement to induce fusion.
    J Virol. 2003 May;77(10):5829-36 PMID: 12719576
  8. Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein.
    Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5016-21 PMID: 12702763
  9. Progressive truncations C terminal to the membrane-spanning domain of simian immunodeficiency virus Env reduce fusogenicity and increase concentration dependence of Env for fusion.
    J Virol. 2003 Jun;77(12):7067-77 PMID: 12768026
  10. HIV-1 resistance to the gp41-dependent fusion inhibitor C-34.
    Antiviral Res. 2003 Jul;59(2):137-42 PMID: 12895697
  11. Regulation of human immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease activity.
    J Virol. 2004 Jan;78(2):1026-31 PMID: 14694135
  12. The 447-52D antibody: hitting HIV-1 where its armor is thickest.
    Structure. 2004 Feb;12(2):173-4 PMID: 14962377
  13. Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D.
    Structure. 2004 Feb;12(2):193-204 PMID: 14962380
  14. Human immunodeficiency virus type 1 envelope glycoproteins that lack cytoplasmic domain cysteines: impact on association with membrane lipid rafts and incorporation onto budding virus particles.
    J Virol. 2004 May;78(10):5500-6 PMID: 15113929
  15. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
    J Mol Biol. 2004 Jun 25;340(1):9-14 PMID: 15184018
  16. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain.
    Cell. 1986 Nov 7;47(3):333-48 PMID: 3094962
  17. Active human immunodeficiency virus protease is required for viral infectivity.
    Proc Natl Acad Sci U S A. 1988 Jul;85(13):4686-90 PMID: 3290901
  18. Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity.
    J Virol. 1989 Jun;63(6):2550-6 PMID: 2657099
  19. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1.
    Proc Natl Acad Sci U S A. 1989 Aug;86(15):5781-5 PMID: 2788277
  20. The cytoplasmic domain of simian immunodeficiency virus transmembrane protein modulates infectivity.
    J Virol. 1989 Oct;63(10):4395-403 PMID: 2778881
  21. SIV adaptation to human cells.
    Nature. 1989 Oct 19;341(6243):573-4 PMID: 2677749
  22. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals.
    Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10134-7 PMID: 1719545
  23. Efficient selection for high-expression transfectants with a novel eukaryotic vector.
    Gene. 1991 Dec 15;108(2):193-9 PMID: 1660837
  24. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody.
    J Virol. 1992 Dec;66(12):7538-42 PMID: 1433529
  25. Atomic structure of the ectodomain from HIV-1 gp41.
    Nature. 1997 May 22;387(6631):426-30 PMID: 9163431
  26. Human immunodeficiency virus envelope-dependent cell-cell fusion: a quantitative fluorescence cytometric assay.
    Cytometry. 2002 Feb 1;47(2):100-6 PMID: 11813199
  27. Mechanisms of viral membrane fusion and its inhibition.
    Annu Rev Biochem. 2001;70:777-810 PMID: 11395423
  28. Altering expression levels of human immunodeficiency virus type 1 gp120-gp41 affects efficiency but not kinetics of cell-cell fusion.
    J Virol. 2002 Apr;76(7):3522-33 PMID: 11884576
  29. A human lymphoid recombinant cell line with functional human immunodeficiency virus type 1 envelope.
    AIDS Res Hum Retroviruses. 1993 Jan;9(1):23-32 PMID: 8094000
  30. Detection and quantitation of cell-cell electrofusion products by flow cytometry.
    Anal Biochem. 1994 Feb 1;216(2):271-5 PMID: 7513970
  31. A trimeric subdomain of the simian immunodeficiency virus envelope glycoprotein.
    Biochemistry. 1995 Nov 21;34(46):14955-62 PMID: 7578108
  32. The CD4-independent tropism of human immunodeficiency virus type 2 involves several regions of the envelope protein and correlates with a reduced activation threshold for envelope-mediated fusion.
    J Virol. 1997 Feb;71(2):1453-65 PMID: 8995671
  33. Core structure of gp41 from the HIV envelope glycoprotein.
    Cell. 1997 Apr 18;89(2):263-73 PMID: 9108481
  34. Expression cloning of new receptors used by simian and human immunodeficiency viruses.
    Nature. 1997 Jul 17;388(6639):296-300 PMID: 9230441
  35. Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop.
    J Virol. 1997 Sep;71(9):7136-9 PMID: 9261451
  36. Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity.
    J Virol. 1999 Dec;73(12):10310-9 PMID: 10559349
  37. Fluorescence-based quantitative methods for detecting human immunodeficiency virus type 1-induced syncytia.
    J Clin Microbiol. 2000 Aug;38(8):3055-60 PMID: 10921977
  38. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.
    J Virol. 2000 Sep;74(18):8358-67 PMID: 10954535
  39. Evidence for a stable interaction of gp41 with Pr55(Gag) in immature human immunodeficiency virus type 1 particles.
    J Virol. 2000 Oct;74(20):9381-7 PMID: 11000206
  40. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion.
    J Cell Biol. 2000 Oct 16;151(2):413-23 PMID: 11038187
  41. Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection.
    Virology. 2000 Oct 25;276(2):229-37 PMID: 11040114
  42. Protein design of an HIV-1 entry inhibitor.
    Science. 2001 Feb 2;291(5505):884-8 PMID: 11229405
  43. Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein.
    J Virol. 2001 Jun;75(11):5230-9 PMID: 11333905
  44. Membrane fusion machines of paramyxoviruses: capture of intermediates of fusion.
    EMBO J. 2001 Aug 1;20(15):4024-34 PMID: 11483506
  45. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor.
    J Virol. 2001 Sep;75(18):8605-14 PMID: 11507206
  46. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.
    Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92 PMID: 11572974
  47. HIV-1 gp41 six-helix bundle formation occurs rapidly after the engagement of gp120 by CXCR4 in the HIV-1 Env-mediated fusion process.
    Biochemistry. 2001 Oct 16;40(41):12231-6 PMID: 11591141
  48. Atomic structure of a thermostable subdomain of HIV-1 gp41.
    Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12303-8 PMID: 9356444
  49. Capture of an early fusion-active conformation of HIV-1 gp41.
    Nat Struct Biol. 1998 Apr;5(4):276-9 PMID: 9546217
  50. A membrane-proximal tyrosine-based signal mediates internalization of the HIV-1 envelope glycoprotein via interaction with the AP-2 clathrin adaptor.
    J Biol Chem. 1998 Jun 19;273(25):15773-8 PMID: 9624176
  51. HIV entry and its inhibition.
    Cell. 1998 May 29;93(5):681-4 PMID: 9630213
  52. Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides.
    Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9134-9 PMID: 9689046
  53. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry.
    Nat Med. 1998 Nov;4(11):1302-7 PMID: 9809555
  54. HIV-1 envelope determinants for cell tropism and chemokine receptor use.
    Mol Membr Biol. 1999 Jan-Mar;16(1):57-65 PMID: 10332738
  55. Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein.
    Proc Natl Acad Sci U S A. 1999 May 25;96(11):6359-64 PMID: 10339592
  56. Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization.
    J Virol. 1999 Oct;73(10):8216-26 PMID: 10482572
  57. CD4-independent use of Rhesus CCR5 by human immunodeficiency virus Type 2 implicates an electrostatic interaction between the CCR5 N terminus and the gp120 C4 domain.
    J Virol. 2001 Nov;75(22):10766-78 PMID: 11602718
  58. The mechanism of inhibition of HIV-1 env-mediated cell-cell fusion by recombinant cores of gp41 ectodomain.
    Virology. 2002 Oct 10;302(1):174-84 PMID: 12429526
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
2005-01-00
Pages
106-15
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC538707
Subset
IM
Grants
NIGMS NIH HHS · GM54787 · United States
NIAID NIH HHS · AI42382 · United States
NIGMS NIH HHS · R01 GM027367 · United States
NIGMS NIH HHS · R29 GM054787 · United States
NIAID NIH HHS · R01 AI042382 · United States
NIAID NIH HHS · R56 AI042382 · United States
NIGMS NIH HHS · GM27367 · United States
NIGMS NIH HHS · R01 GM054787 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com